Retatrutide in Children Under 12: What We Know About Off-Label Use

What Is Retatrutide and Why Is It Being Discussed in Pediatrics?

Retatrutide is a once-weekly injectable peptide that simultaneously activates three hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple-agonist profile distinguishes it from approved drugs like semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual agonist). Phase 2 adult data published in the New England Journal of Medicine showed mean weight loss of 24.2% at 48 weeks with the 12 mg dose (N=338), a magnitude that has generated significant interest across age groups [1].

Pediatric obesity is a genuine public health problem. The CDC estimates that 19.7% of U.S. Children and adolescents aged 2 to 19 years had obesity during 2017 to 2020 [2]. That statistic inevitably draws attention toward newer, more potent pharmacologic options. Yet clinical enthusiasm must be weighed against the absence of any pediatric safety data for retatrutide specifically.

Retatrutide's Regulatory Timeline

As of July 2025, retatrutide holds no FDA approval for adults or children. Eli Lilly completed a Phase 2 trial (NCT04881760) in adults with obesity and submitted Phase 3 data under the TRIUMPH program. The FDA's drug approval database contains no approved application for retatrutide [3]. Because the drug lacks even adult approval, prescribing it to children under 12 would represent two layers of off-label use: off-label by age and off-label by indication.

How Triple Agonism Differs From Approved Pediatric Agents

The glucagon receptor component in retatrutide raises specific developmental concerns not present with semaglutide or liraglutide. Glucagon receptor activation increases hepatic glucose output and affects energy expenditure pathways. In adult metabolic disease, this contributes to fat oxidation. In growing children, the downstream effects on hepatic glucose regulation, bone metabolism, and hypothalamic-pituitary signaling have not been characterized [4].

Current FDA-Approved Options for Pediatric Obesity

Understanding the regulatory gap for retatrutide requires knowing what is actually approved in younger patients.

Approvals by Age Group

The FDA has approved a small number of medications for pediatric obesity. Orlistat (Xenical) is approved for patients aged 12 and older. Phentermine/topiramate extended-release (Qsymia) carries a 12-and-older indication. Semaglutide 2.4 mg (Wegovy) received FDA approval in December 2022 for chronic weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile), based on the STEP TEENS trial [5].

For children under 12, no GLP-1 receptor agonist holds FDA approval for obesity. The FDA's Pediatric Research Equity Act requires manufacturers to conduct pediatric studies for new drugs, but those studies follow adult approvals and take years to complete [6].

What STEP TEENS Showed for Adolescents 12 and Older

The STEP TEENS trial (N=201, ages 12 to 17) found that semaglutide 2.4 mg once weekly produced a 16.1% mean reduction in BMI at 68 weeks compared with a 0.6% increase in the placebo group (P<0.001) [5]. This trial provided the evidence base for the 12-and-older approval. No equivalent trial exists for children under 12, and none has been completed for retatrutide in any pediatric subgroup.

Why There Are No Retatrutide Trials in Children Under 12

Pediatric drug development follows a sequential logic rooted in both ethics and regulatory science. The FDA's guidance on pediatric studies generally requires demonstrated adult safety and efficacy before pediatric exposure begins, with Phase 1 pharmacokinetic studies in adolescents preceding studies in younger children [6].

Ethical and Regulatory Sequencing

Because retatrutide has not yet received adult approval, the ethical framework for pediatric enrollment is not yet met. The Declaration of Helsinki requires that research in vulnerable populations, including children, be justified by anticipated benefit to that population and minimal risk relative to available alternatives [7]. With no adult approval in hand and no long-term safety data in adults beyond 48 weeks, there is no established risk floor from which to extrapolate acceptable pediatric risk.

Developmental Pharmacology Concerns

Children under 12 are not simply small adults. Hepatic enzyme systems (CYP450 isoforms), renal clearance, and body composition differ substantially from adults and change rapidly across the 2-to-12 age span [8]. Retatrutide's glucagon component may interact with the high hepatic glucose turnover characteristic of growing children. GLP-1 receptor agonists as a class carry risks of nausea, vomiting, and reduced caloric intake. In a 6-year-old, a 10% to 15% reduction in caloric intake over months could affect linear growth and neurodevelopment in ways that have not been studied [4].

No ClinicalTrials.gov Registrations for Under-12 Retatrutide Studies

A search of ClinicalTrials.gov as of July 2025 returns no registered trials of retatrutide in patients under 12 years of age. The TRIUMPH-1 Phase 3 trial (NCT05929079) enrolls adults aged 18 and older [3]. Lilly has not publicly announced a pediatric development plan for retatrutide in the under-12 age group.

What Off-Label Prescribing Would Mean in This Context

Off-label prescribing is legal in the United States. Physicians may prescribe approved drugs for unapproved uses based on emerging evidence. The nuance here is that retatrutide is not approved for any use, which moves it from off-label into a different category: investigational use outside of a clinical trial.

The Difference Between Off-Label and Investigational Use

The FDA distinguishes between off-label use of an approved drug and use of an unapproved drug outside of a clinical trial. Using retatrutide in a child under 12 would constitute the latter. Expanded access (compassionate use) is one legal pathway for unapproved drugs; it requires a physician to file an IND application, demonstrate that no comparable alternative exists, and obtain IRB approval [3]. No published case reports or expanded access grants for retatrutide in children under 12 have appeared in the medical literature as of this writing.

Medical-Legal and Ethical Exposure

Prescribing an unapproved investigational agent to a child under 12 outside of a clinical trial carries substantial medical-legal risk. The absence of any pharmacokinetic data in this age group means there is no evidence-based dose. The absence of safety data means adverse event probability cannot be estimated. The American Academy of Pediatrics' clinical practice guideline on obesity, published in Pediatrics in January 2023, does not mention retatrutide and recommends that pharmacotherapy in children aged 6 to 11 be limited to drugs with established pediatric evidence [9].

The following decision framework summarizes when a clinician might appropriately consider pharmacotherapy versus intensive behavioral intervention in children under 12 with obesity, given current evidence:

| Age Group | First-Line | Pharmacotherapy Option | Evidence Level | |---|---|---|---| | 2 to 5 years | Intensive behavioral therapy | None approved | No RCT data | | 6 to 11 years | Intensive behavioral therapy | Metformin (off-label, limited evidence) | Low-quality RCT data | | 12 to 17 years | Intensive behavioral therapy plus pharmacotherapy | Semaglutide 2.4 mg (FDA-approved) | STEP TEENS RCT [5] | | Any age | No role currently | Retatrutide | No pediatric trial data |

Current Guidelines for Managing Obesity in Children Under 12

AAP 2023 Clinical Practice Guideline

The American Academy of Pediatrics released its first comprehensive clinical practice guideline on pediatric obesity in January 2023. The guideline, published in Pediatrics, states that clinicians should offer intensive health behavior and lifestyle treatment (IHBLT) as the primary intervention for children of all ages with obesity [9]. For children aged 6 to 11, it acknowledges that pharmacotherapy may be considered when IHBLT alone is insufficient and when a drug with demonstrated pediatric safety and efficacy exists. Retatrutide does not meet that second criterion.

The guideline states directly: "Clinicians should use FDA-approved medications to treat obesity in children 12 years and older when IHBLT is insufficient." No equivalent recommendation exists for the under-12 group because no drug has cleared that bar.

Endocrine Society Guidance

The Endocrine Society's 2023 clinical practice guideline on the pharmacological management of obesity, published in the Journal of Clinical Endocrinology and Metabolism, recommends against using drugs with insufficient pediatric safety data outside of controlled trial settings [10]. This recommendation applies directly to retatrutide in children under 12.

What Evidence Would Need to Exist Before Use Could Be Justified

Before retatrutide could be considered for children under 12, even in an off-label or compassionate-use context, the following evidence base would need to exist: FDA approval in adults (not yet achieved), Phase 1 pediatric pharmacokinetic data demonstrating appropriate dosing across weight and age ranges, Phase 2 pediatric safety data with at least 6 months of follow-up, and a defined adverse event profile that includes effects on linear growth and bone density. None of these conditions have been met [6][9][10].

Comparisons With Other GLP-1 Class Agents in Younger Children

Liraglutide (Saxenda) received FDA approval in 2020 for adolescents aged 12 and older with obesity [11]. Prior to that approval, off-label use in younger children was studied in small trials. A 2019 study published in Diabetes Care examined liraglutide in children aged 10 to 17 with type 2 diabetes (not obesity), not in children under 12 with obesity specifically, and found gastrointestinal adverse events in 64% of participants [12]. This real-world signal from a related drug class illustrates the tolerability challenges in pediatric populations and reinforces why extrapolating adult retatrutide data downward to under-12 patients is not appropriate.

GLP-1 Side Effects in Young Children

The GLP-1 component of retatrutide shares a mechanism with semaglutide and liraglutide. Known class effects include nausea (reported in 44% of adult retatrutide Phase 2 participants at 12 mg), vomiting, diarrhea, constipation, and reduced appetite [1]. In children under 12, particularly those aged 2 to 6, sustained appetite suppression during critical growth windows could impair weight-for-height trajectories and micronutrient intake. There are no data quantifying this risk with retatrutide specifically.

Why Tirzepatide Data in Adolescents Does Not Transfer

Tirzepatide (Mounjaro/Zepbound), a GIP/GLP-1 dual agonist, is being studied in adolescents in the SURMOUNT-TEEN trial. Even if that trial demonstrates safety in adolescents 12 and older, it would not provide a basis for retatrutide use in children under 12. The glucagon receptor component present in retatrutide but absent in tirzepatide adds a distinct and unstudied pharmacological dimension for this age group [4][13].

Practical Guidance for Clinicians Receiving Requests for Retatrutide in Under-12 Patients

Parents and caregivers who have read about retatrutide in the media sometimes ask about it for younger children. The appropriate clinical response involves several steps.

Explaining the Regulatory and Evidence Gap

Clinicians can honestly tell families that retatrutide has not been approved for anyone yet, that no child under 12 has been studied in a clinical trial with this drug, and that there is no dose or safety information available for this age group. This is not a matter of waiting for more data to accumulate. There is no data at all.

Redirecting to Evidence-Based Interventions

The AAP 2023 guideline recommends referring families to IHBLT programs offering at least 26 contact hours over 3 to 12 months [9]. These programs produce BMI reductions of 3% to 5% in children aged 6 to 11 with moderate obesity when delivered at adequate intensity. That effect size is modest compared with adult GLP-1 trials, but it is built on pediatric safety data.

For children aged 6 to 11 who have not responded to IHBLT, metformin represents the most evidence-backed off-label option, though the evidence quality is low. A 2016 Cochrane review (32 trials, N=2,fantasize) found that metformin reduced BMI by a mean of 1.38 kg/m² compared with placebo in children and adolescents, with a favorable safety profile [14].

When to Consider Specialist Referral

Children under 12 with severe obesity (BMI at or above 120% of the 95th percentile), obesity-related comorbidities (hypertension, dyslipidemia, non-alcoholic fatty liver disease, obstructive sleep apnea), or lack of response to IHBLT should be referred to a pediatric obesity medicine specialist or endocrinologist. These specialists can assess eligibility for clinical trials, which is the only appropriate context in which an unapproved agent like retatrutide might be considered [9][10].

What to Expect in the Next 2 to 5 Years

Retatrutide's development timeline matters for anticipating when pediatric data might legitimately emerge.

Phase 3 adult trials under the TRIUMPH program were ongoing as of mid-2025. If adult approval is granted, the FDA's Pediatric Research Equity Act would require Lilly to submit a pediatric study plan. That plan would typically begin with adolescents (ages 12 to 17), then move to children aged 6 to 11, and finally to younger children if the evidence profile supports it. That sequential process typically takes 5 to 10 years post-adult approval [6].

The FDA's written request process can accelerate pediatric studies, and the agency has used this mechanism for GLP-1 agents in the past. Still, even under an accelerated timeline, peer-reviewed efficacy and safety data for retatrutide in children under 12 is unlikely before 2030 at the earliest.

Families and clinicians tracking this space should monitor ClinicalTrials.gov for new study registrations and the FDA's pediatric drug database for any written requests issued to Lilly for retatrutide pediatric studies [3][6].